Welcome to our dedicated page for Sophia Genetics Sa SEC filings (Ticker: SOPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing SOPHiA GENETICS’ filings can feel like decoding the human genome itself—dense pages on machine-learning algorithms, data-privacy controls, and global regulatory paths. If you’ve ever asked, “How do I read the SOPHiA GENETICS annual report 10-K simplified?” or searched for “SOPHiA GENETICS insider trading Form 4 transactions,” this page was built for you.
Stock Titan’s AI instantly converts every new document—whether a 10-Q quarterly earnings report or an 8-K material event—into plain-English highlights. Want segment metrics on cloud-based diagnostics? Our engine flags them. Tracking “SOPHiA GENETICS executive stock transactions Form 4” before a pipeline announcement? Real-time alerts mean you never miss a trade.
Here’s what you’ll uncover:
- 10-K & 10-Q: Drill into R&D spend, SaaS subscription growth, and data-security disclosures with our AI-powered summaries—perfect for anyone Googling “understanding SOPHiA GENETICS SEC documents with AI.”
- Form 4: Live feed of “SOPHiA GENETICS Form 4 insider transactions real-time,” tracking how executives manage equity tied to precision-oncology milestones.
- Proxy statements: Clarity on “SOPHiA GENETICS proxy statement executive compensation,” including stock-option grants for bioinformatics talent.
- 8-K events: Immediate context when the company files “SOPHiA GENETICS 8-K material events explained,” whether it’s a new hospital network partnership or regulatory approval update.
Every filing is refreshed straight from EDGAR the moment it posts. Our concise AI commentary surfaces what drives revenue, highlights key risk factors, and answers common questions like “SOPHiA GENETICS earnings report filing analysis” without forcing you to wade through footnotes. Complex genomics disclosures made clear—so you can focus on decisions, not documentation.
SOPHiA GENETICS SA prospectus supplement discloses share capital, equity incentives and corporate governance provisions relevant to debt and equity offerings. As of June 30, 2025 the company reported options and awards that could dilute equity: 495,980 shares from an Incentive Stock Option Plan (WAEP $3.18), 2,295,990 from a 2019 plan (WAEP $4.97), 11,558,048 from a 2021 Equity Incentive Plan (WAEP $5.79), 3,194,328 RSUs, 3,838,901 additional shares reserved under the 2021 plan, 400,000 warrants (exercise $4.9992) and 11,741,660 treasury shares.
The filing also describes shareholder authority and board powers, authorized conditional share capital and a capital range enabling the board to increase or decrease share capital by up to 50% within a shareholder-determined period not exceeding five years. It lists circumstances permitting issuance without pre-emptive rights, permitted offering methods, and certain exemptions and Exchange Act obligations applicable if the company ceases to qualify as a foreign private issuer.
Schedule 13G filing: On 27 June 2025 Akre Capital Management, LLC (ACM), Braddock Partners Offshore, LP and Braddock Capital Offshore, LLC jointly filed a Schedule 13G reporting a beneficial position in SOPHiA GENETICS SA (CUSIP H82027105).
The reporting persons collectively hold 3,719,140 ordinary shares, representing 5.6 % of the outstanding class. All voting and dispositive authority over the shares is shared; each entity reports zero sole voting or dispositive power and full shared power over the entire stake, triggering the 5 % disclosure threshold under Section 13(d).
ACM is organized in Delaware and operates as an investment adviser, while Braddock Partners Offshore, LP is a Cayman Islands limited partnership and Braddock Capital Offshore, LLC is a Delaware limited-liability company. The certification states that the securities were acquired ‘not for the purpose of or with the effect of changing or influencing the control’ of the issuer. No additional group members, subsidiary acquisitions, or 5 %-or-less disclaimers are indicated. An Exhibit A Joint Filing Agreement accompanies the submission.
Form 144 overview: SOPHiA GENETICS SA (ticker SOPH) has filed a Form 144 indicating the proposed sale of insider-held shares under Rule 144 of the Securities Act of 1933.
- Seller & relationship: The filing lists one unnamed insider ("person for whose account the securities are to be sold"). No further relationship data is provided in the snippet.
- Securities to be sold: 18,443 shares of common stock.
- Estimated market value: USD 56,066.72, implying an indicative share price of roughly USD 3.04.
- Broker: Morgan Stanley Smith Barney LLC, Executive Financial Services, New York.
- Planned trade date & venue: On or about 20 June 2025 on the NASDAQ.
- Shares outstanding: 66,687,085. The proposed sale represents approximately 0.028% of total shares outstanding—not material from a dilution perspective.
- Source of shares: Restricted Stock Units acquired 18 June 2025; not a gift.
- Prior 3-month sales: The filer reports "Nothing to Report," indicating no other recent insider sales by this individual that must be aggregated.
Investor takeaway: The filing signals a routine disposal of a small block of shares by an insider. Given the limited size relative to total float and the absence of any cited adverse information, the market impact is likely negligible. Nevertheless, investors monitoring insider activity may note the transaction when evaluating sentiment and liquidity conditions.
SOPHiA GENETICS SA (SOPH) filed a Form 144 indicating that Ross J. Muken intends to sell up to 14,509 common shares through Morgan Stanley Smith Barney on or about 20 June 2025. At the most recent market price reflected in the filing, the shares have an aggregate value of $44,107.36. The company has 66,687,085 shares outstanding, meaning the proposed sale represents roughly 0.02 % of shares outstanding.
The filing also discloses that, under a Rule 10b5-1 trading plan, Muken has sold 14,542 shares in the prior three months for total gross proceeds of approximately $40,660. The current notice confirms the seller’s representation that no undisclosed material adverse information is known at the time of the planned sale.
Because the transaction size is modest relative to the company’s share count and is executed under a pre-arranged trading plan, the filing is routine and unlikely to have a material impact on SOPH’s capital structure or stock liquidity.
FAQ
What is the current stock price of Sophia Genetics Sa (SOPH)?
What is the market cap of Sophia Genetics Sa (SOPH)?
